v3.25.2
SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)
3 Months Ended
Jun. 02, 2025
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
AUD ($)
Jun. 30, 2025
EUR (€)
Mar. 31, 2025
USD ($)
Product Information [Line Items]            
Net cash used in operating activities   $ (4,526,000) $ (10,180,000)      
Accumulated deficit   294,013,000       $ 286,322,000
Cash equivalents   6,500,000        
Cash deposit   $ 4,000,000.0        
Concentration risk benchmark description   As of June 30, 2025, the Company had greater than $250,000 at United States financial institutions, less than A$250,000 at Australian financial institutions, greater than €100,000 at Irish financial institutions and also has funds on deposit in Israel.        
Accounts Payable [Member] | Customer Concentration Risk [Member] | Two Third-party Vendors [Member]            
Product Information [Line Items]            
Concentration percentage   89.00% 33.00%      
Accounts Payable [Member] | Customer Concentration Risk [Member] | One Third Party Vendors [Member]            
Product Information [Line Items]            
Concentration percentage     56.00%      
Accounts Payable [Member] | Customer Concentration Risk [Member] | One Third Party Vendor [Member]            
Product Information [Line Items]            
Concentration percentage     87.00%      
Australian Taxation Office [Member]            
Product Information [Line Items]            
Tax Rebate   $ 100,000 $ 0      
UNITED STATES            
Product Information [Line Items]            
Cash FDIC insured amount   250,000        
AUSTRALIA            
Product Information [Line Items]            
Cash FDIC insured amount       $ 250,000    
BERMUDA            
Product Information [Line Items]            
Cash FDIC insured amount   25,000        
IRELAND            
Product Information [Line Items]            
Cash FDIC insured amount | €         € 100,000  
CYPRUS            
Product Information [Line Items]            
Cash FDIC insured amount | €         € 100,000  
Director [Member]            
Product Information [Line Items]            
Advanced financing $ 2,000,000.0          
Contract Manufacturer [Member]            
Product Information [Line Items]            
Restricted cash   $ 200,000       $ 200,000
Beyond Cancer Ltd [Member]            
Product Information [Line Items]            
Non-controlling owners interest   20.00%   20.00% 20.00%  
NeuroNos Ltd [Member]            
Product Information [Line Items]            
Non-controlling owners interest   11.80%   11.80% 11.80%